10-K · February 26, 2026
Ironwood Pharmaceuticals, Inc. reported a total revenue of $296.2 million for the year ended December 31, 2025, a decline from $351.4 million in 2024, primarily due to a $51.1 million decrease in profit shares from…
Earnings analysis · 10-Q
IRWD earnings analysis
Filed May 7, 2026 · Our reading of the company's report
The latest report
Ironwood Pharmaceuticals reported a strong Q1 2026, beating revenue estimates with total revenues of $106.5 million and achieving diluted EPS of $0.24, surpassing the forecast of $0.21. The company maintains its…
Read full summary
Ironwood Pharmaceuticals reported a strong Q1 2026, beating revenue estimates with total revenues of $106.5 million and achieving diluted EPS of $0.24, surpassing the forecast of $0.21. The company maintains its full-year revenue guidance of $450 million to $475 million, signaling confidence in sustained performance due to strong sales from LINZESS.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $0.24
- Segment
- LINZESS sales
- Segment
- collaborative arrangements revenue
What stood out
-
Revenue Surged by 258%
Total revenue reached $106.5 million, up from $41.1 million in Q1 2025.
-
EPS Outperformed Expectations
Diluted EPS was reported at $0.24, exceeding the consensus estimate of $0.21.
-
Decreased Operating Expenses
Operating expenses totaled $33.9 million, down from $70.3 million year-over-year.
-
Strong LINZESS Performance
Increased revenues of $65.5 million attributed to enhanced net pricing and prescription demand for LINZESS.
-
Positive Net Income Reported
Net income for Q1 2026 was $40.8 million, a turnaround from a loss of $37.4 million in Q1 2025.
-
Improved Cash Flow
Operating cash flow for the quarter was positive at $5.1 million, although down from $20 million a year ago.
What to watch
-
Rising Interest Expenses
Interest expense increased to $9.1 million from $8.1 million in Q1 2025.
-
Accumulated Deficit Remains High
The company has an accumulated deficit of approximately $1.6 billion as of March 31, 2026.
-
High Dependency on LINZESS
Revenues are primarily dependent on LINZESS, raising concerns over market competition risks.
Management's outlook
Full-year 2026 revenue guidance maintained at $450M to $475M.
Earlier filings 4
10-Q · November 10, 2025
Ironwood Pharmaceuticals reported impressive Q3 2025 results, with revenues of $122.06 million, significantly surpassing expectations and marking a notable 94.5% increase from the prior quarter and a 32.7% increase…
10-Q · August 11, 2025
Ironwood Pharmaceuticals reported strong Q2 2025 results with net income of $23.6 million compared to a loss of $0.9 million in Q2 2024. Revenue surged to $85.2 million, up from $75 million in Q1 2025, primarily driven…
10-Q · May 12, 2025
Ironwood Pharmaceuticals reported a significant decline in revenue and higher losses in Q1 2025 compared to the previous year. Total revenue dropped to $41.1 million from $74.9 million a year ago, while net losses…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.